Clinical trial
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases…
NCT00242567 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00242567 |
|---|---|
| Title | Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer |
| Official title | A Phase III, Parallel Group, Randomized, Open-label, Multi-centre Clinical Trial of Zoledronic Acid in Males Receiving Androgen Deprivation Therapy for Advanced Prostate Cancer. |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Zoledronic Acid, Androgen Deprivation Therapy (ADT) |
| Enrollment | 522 |
| Start date | Dec 1, 2005 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Oct 20, 2005 |
| Last update posted | May 7, 2014 |
| Countries | Australia, Brazil, China, Kuwait, Lebanon, New Zealand, Saudi Arabia, South Korea, Taiwan, Thailand |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: